News
Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...
Immutep Limited (NASDAQ:IMMP) is among the 12 Best Australian Stocks to Buy Right Now. On August 5, the company shared that ...
Exelixis, Inc. (NASDAQ:EXEL) is one of the best growth stocks to buy according to analysts. On August 12, H.C. Wainwright ...
Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...
1d
TipRanks on MSNPfizer’s Latest Clinical Trial: A New Hope for KRAS-Mutated Tumors
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a Phase 1 open-label study ...
Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.
The pivotal Phase 3 trial for Cylembio® in advanced melanoma showed clinical improvement in progression free survival, but missed its primary endpoint for statistical significance (p=0.056; threshold ...
A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...
Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...
Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...
Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results